Apoptosis is the genetically determined form of controlled cellular elimination that accounts for most of the cell death that takes place in-vivo. It is also the primary mechanism of cell death during the in-vitro cultivation of mammalian cell lines used in the production of biopharmaceuticals. In recent years, lab scale studies have indicated that the suppression of the apoptotic pathway during the synthesis of these high value products can substantially increase the productivity of the culture process. In the demonstration proposed here, we will develop new cell lines that incorporate anti-apoptosis genes and will demonstrate the impact of this strategy on the efficiency of state of the art industrial-scale biopharmaceucical production processes, and then make them available to the biotechnology industry.
- Assessment of transfectants over-expressing Bcl-2 protein, generated in previous programme, in a state-of-the-art biopharmaceutical manufacturing process was completed;
- Bank of NS0 clones expressing different levels of Bcl-2 protein secured and selected clones characterised.
Funding SchemeDEM - Demonstration contracts
SL1 4DI Slough